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PreviewsClec12a (Neumann et al., 2014), other
intracellular sensor(s) for MSU might be
operating in the negative regulation of
inflammasome-caspase-1 axis. MSU is
characterized as an endogenous adjuvant
that promotes acquired immune re-
sponses (Shi et al., 2003). Because
Clec12a is also expressed in dendritic
cells, it would be valuable to examine
whether Clec12a can inhibit T cell-medi-
ated immunity by regulating antigen-
presenting cells.
These findings shed light on ITIM-con-
taining CLRs as important negative regu-
lators that potentially dampen immune
responses against DAMPs. The develop-
ment of selective agonist for Clec12a is
of interest in the treatment of a variety ofinflammatory diseases associated with
high systemic uric acid levels, such as
arthritis, atherosclerosis, cardiovascular
diseases, and type 2 diabetes.REFERENCES
Barabe´, F., Gilbert, C., Liao, N., Bourgoin, S.G.,
and Naccache, P.H. (1998). FASEB J. 12, 209–220.
Marshall, A.S., Willment, J.A., Pyz, E., Dennehy,
K.M., Reid, D.M., Dri, P., Gordon, S., Wong, S.Y.,
and Brown, G.D. (2006). Eur. J. Immunol. 36,
2159–2169.
Martinon, F., Pe´trilli, V., Mayor, A., Tardivel, A., and
Tschopp, J. (2006). Nature 440, 237–241.
Neumann, K., Castin˜eiras-Vilarin˜o, M., Ho¨cken-
dorf, U., Hannesschla¨ger, N., Lemeer, S., Kupka,
K., Meyermann, S., Lech, M., Anders, H.-J., Kus-Immunity 4ter, B., et al. (2014). Immunity 40, this issue,
389–399.
Pyz, E., Huysamen, C., Marshall, A.S., Gordon, S.,
Taylor, P.R., and Brown, G.D. (2008). Eur. J.
Immunol. 38, 1157–1163.
Robinson, M.J., Sancho, D., Slack, E.C.,
LeibundGut-Landmann, S., and Reis e Sousa, C.
(2006). Nat. Immunol. 7, 1258–1265.
Sancho, D., Joffre, O.P., Keller, A.M., Rogers, N.C.,
Martı´nez, D., Hernanz-Falco´n, P., Rosewell, I., and
Reis e Sousa, C. (2009). Nature 458, 899–903.
Shi, Y., Evans, J.E., and Rock, K.L. (2003). Nature
425, 516–521.
Shi, Y., Mucsi, A.D., and Ng, G. (2010). Immunol.
Rev. 233, 203–217.
Yamasaki, S., Ishikawa, E., Sakuma, M., Hara, H.,
Ogata, K., and Saito, T. (2008). Nat. Immunol. 9,
1179–1188.Dendritic Cells Decide CD8+ T Cell FateAllan McI. Mowat1,*
1Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Sir Graeme Davies Building,
Glasgow G12 8TA, Scotland, UK
*Correspondence: allan.mowat@glasgow.ac.uk
http://dx.doi.org/10.1016/j.immuni.2014.02.011
In this issue of Immunity, Kim et al. (2014) propose that CD103+ DCs in mouse lung selectively generate
effector CD8+ T cells by binding the alarmin HMGB1 via CD24 and presenting it to RAGE+ T cells.Whether the same dendritic cell (DC) can
prime all kinds of T cells or whether indi-
vidual T cell populations require antigen
to be presented by separate populations
of DCs has long been an issue in immu-
nology. Addressing these questions is
important not just for understanding the
basic tenets of immune function, but
also for identifying which DC might be
useful to target in designing vaccines or
tailoring immunotherapy.
In this issue of Immunity, Kim et al.
(2014) show that separate DC subsets
in the influenza A virus (IAV)-infected lung
may play distinct roles in driving local
effector ormemoryCD8+Tcell responses.
Whereas CD103+CD11b DCs generate
short-lived CD8+ effector T cells that
home to the lung and confer protective
immunity, CD103CD11b+ DCs drive the
generation of ‘‘central memory’’ CD8+
T cells that reside in secondary lymphoid
organs for long periods after infection.The CD103+ DCs that drive effector CD8+
T cell differentiation express very high
amounts of CD24; blockade and overex-
pression of CD24 show that the amount
of CD24 controls whether effector or
memory CD8+ T cells are generated by
the same virus challenge. It is proposed
that CD24 acts by allowing CD103+ DCs
to decorate their surfacewith highmobility
group box 1 (HMGB1) protein, a histone-
related protein that acts as a damage-
associated molecular pattern (DAMP)
molecule when released from dying cells
in the lung (Ullah et al., 2014) and whose
receptor, RAGE (receptor for advanced
glycation endproducts), can act as a cos-
timulatory signal in T cells (Moser et al.,
2007). Kim et al. (2014) then demonstrate
that blocking the interaction between
CD24, HMGB1, and RAGE markedly in-
hibits priming of CD8+ T cells in vivo and
in vitro. The authors conclude thatCD103+
DCs can thus provide the strong signalneeded to generate effector CD8+ T cells
(Figure 1). It is known that efficient T cell
priming and high amounts of IL-2 produc-
tion favor the differentiation of short-lived
effector versus long-lived memory CD8+
T cells (Kalia et al., 2010). This has usually
been assumed to reflect differences in
the TCR-pMHC interaction. The work of
Kim et al. (2014) now suggests that
such decisions are not controlled simply
via the TCR, but involve additional non-
antigen-specific costimulatory processes
such as the CD24-HMGB1-RAGE axis.
The current work may also help explain
apparent contradictions in the literature
about how CD103+ and CD11b+ DCs
may divide their labor in CD8+ T cell
responses in the lung. Although a con-
sensus has subsequently arisen that
migratory CD103+ DCs play the dominant
role in priming CD8+ T cell responses in
the MedLN, a role for migratory CD11b+
DCs has also long been suspected0, March 20, 2014 ª2014 Elsevier Inc. 311
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Figure 1. CD24 Drives Differentiation of CD8+ T Effector Cells by CD103+ DCs in the Lung
Respiratory epithelial cells are infected and killed by influenza virus A (IAV) before being taken up by
CD103+ and CD11b+ DCs in the vicinity. Both DC subsets can then migrate to the draining mediastinal
lymph node (MeLN), where they present viral antigens to CD8+ T cells. However, only CD103+ DCs induce
the differentiation of effector CD8+ T cells that will return to the lung to eradicate the virus. This is because
CD103+ DCs express high amounts of CD24 that binds the alarmin HMGB1 released by infected respira-
tory cells. As a result, CD103+CD24hi DCs become decorated by HMGB1, which is recognized by RAGE
on cognate CD8+ T cells, costimulating the high amounts of IL-2 and IL-2R needed for the differentiation
of effector T cells. CD11b+CD24lo DCs do not drive the same amount of IL-2, leading to central memory
CD8+ T cells that remain in the MedLN.
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Previews(Neyt and Lambrecht, 2013). It has been
proposed that whereas CD103+ DCs are
required for the earliest stage of CD8+
T cell priming, the CD11b+ subset is
involved in a second wave of T cell activa-
tion (Ballesteros-Tato et al., 2010). Kim
et al. (2014) now suggest that both DC
subsets migrate to the draining LN soon
after influenza infection but that they
specify different fates for the naive CD8+
T cells they encounter. Thus, the division
of labor between CD103+ and CD11b+
DCs may ensure rapid generation of the
effector T cells needed to clear acute
infection in the tissue, followed by slower
development of the cells needed for sus-
tained memory.
CD103+ DCs are known to express
particularly high amounts of CD24
(Tamoutounour et al., 2012) and CD24
has been considered to act as a costimu-
latory molecule in T cell-APC interactions.
Kim et al. (2014) now propose amolecular312 Immunity 40, March 20, 2014 ª2014 Elsebasis for this process, by showing that
CD24 allows CD103+ DCs to decorate
themselves with HMGB1 so that it can
be presented to T cells expressing
RAGE. This pathway offers insights into
how CD103+ DCs might function in virus
infections in the lung. Because this popu-
lation is believed to associate particularly
with the respiratory epithelium (Neyt and
Lambrecht, 2013), an ability to bind and
make use of DAMPs such as HMGB1
released by damaged cells could allow
CD103+ DCs to form an important link
between the innate and adaptive immune
system in the lung.
It would now be interesting to study
whether similar processes define CD8+
effector versus memory T cell differentia-
tion in other pulmonary virus infections
or during CD4+ T cell responses such as
allergic lung disease. Similarly, do these
pathways also apply to other body sur-
faces where CD103+ DCs are prevalent?vier Inc.It would also be interesting to know
whether other costimulatory pathways
via (for example) CD28, CD40L, or CD70
can allow DCs to define T cell fate in
a subset-specific manner. The authors
also point out that blocking recognition
of HMGB1 by RAGE does not completely
mirror the effects of CD103+ DCs, raising
the question of whether HMGB1 is unique
among tissue alarmins in its ability to link
T cell differentiation with DCs and innate
immunity. Finally, these intriguing findings
might be exploited practically, perhaps
via CD24 and/or HMGB1 to target
CD103+ DCs for therapy in persistent vi-
rus infections, or in vaccine development.
Although CD103+ DCs with cross presen-
tation activity have not been identified
directly in human lung, such cells are pre-
sent in the human intestine (Watchmaker
et al., 2014) and an analogous population
of CD141+ DCs with a similar genetic pro-
file can be found in human lung (Haniffa
et al., 2012). These cells could now be
used to investigate for the expression
and function of CD24 as well as the
HMGB1-RAGE axis in health and disease.REFERENCES
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